Investor Presentaiton slide image

Investor Presentaiton

For personal use only Recent milestones and near-term catalysts TELIX PHARMACEUTICALS Recently completed milestones . Illuccix regulatory approvals granted in US and Australia HCPCS1 reimbursement submitted for Illuccix in the US ProstACT patient recruitment commenced Distributors finalised for major EU markets (subject to regulatory approval) FDA Investigational New Drug (IND) granted for STARLITE 1 & 2 studies for renal cancer therapy Upcoming milestones: Q1 2022 · • Illuccix commercial launch US and AU US reimbursement for Illuccix: • Pass-through code submission (March 2022) HCPCS code for US reimbursement expected 1 April 2022 Illuccix EU marketing authorisation decision ZIRCON Phase III study enrolment completed IPAX-2 Phase II study launched (glioblastoma) STARLITE Phase II kidney cancer therapy studies progressed 1. Healthcare Common Procedure Coding System Telix Pharmaceuticals Limited (ASX: TLX) 80
View entire presentation